Literature DB >> 26311016

Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer.

Scott L Purga1, Navneet Narula2, Evelyn M Horn3, Maria G Karas3.   

Abstract

A 78-year-old woman with metastatic low-grade serous ovarian cancer presented with rapidly progressive exertional dyspnoea and hypoxia, and was found to have new-onset severe pulmonary hypertension (PH) by right heart catheterisation. A diagnosis of pulmonary tumour thrombotic microangiopathy (PTTM) was made at autopsy. PTTM is a rare complication of advanced cancer that often presents as rapidly progressive PH or acute hypoxic respiratory failure. Widespread tumour cell emboli in the pulmonary arteries and arterioles are hypothesised to induce fibrocellular subintimal proliferation and microthrombi, leading to increased pulmonary vascular resistance and PH. PTTM arising from serous ovarian cancer is exceedingly rare, with only two previously reported cases. A discussion of the pathophysiology, diagnosis and management of PTTM is presented. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26311016      PMCID: PMC4551019          DOI: 10.1136/bcr-2015-211890

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib.

Authors:  Aiko Ogawa; Ichiro Yamadori; Osamu Matsubara; Hiromi Matsubara
Journal:  Intern Med       Date:  2013       Impact factor: 1.271

2.  Pulmonary tumor thrombotic microangiopathy: FDG-PET/CT findings.

Authors:  Yoshiko Tashima; Koichiro Abe; Yoshio Matsuo; Shingo Baba; Koichiro Kaneko; Takuro Isoda; Hidetake Yabuuchi; Masayuki Sasaki; Hiroshi Honda
Journal:  Clin Nucl Med       Date:  2009-03       Impact factor: 7.794

3.  Ventilation-perfusion mismatch in tumor embolism.

Authors:  R J Boudreau; R Lisbona; H Sheldon
Journal:  Clin Nucl Med       Date:  1982-07       Impact factor: 7.794

Review 4.  Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature.

Authors:  Katsuya Chinen; Yasuharu Tokuda; Masachika Fujiwara; Yasunori Fujioka
Journal:  Pathol Res Pract       Date:  2010-06-15       Impact factor: 3.250

5.  Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer.

Authors:  Hiroyuki Abe; Rumi Hino; Masashi Fukayama
Journal:  Virchows Arch       Date:  2013-03-28       Impact factor: 4.064

6.  Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients.

Authors:  S Z Goldhaber; E Dricker; J E Buring; K Eberlein; J J Godleski; R J Mayer; C H Hennekens
Journal:  Am Heart J       Date:  1987-12       Impact factor: 4.749

7.  Pulmonary tumor thrombotic microangiopathy in patients with low-grade ovarian serous neoplasm: a clinicopathologic review of 2 cases of a previously unknown association.

Authors:  Alejandro A Gru; Rish K Pai; Andres A Roma
Journal:  Int J Gynecol Pathol       Date:  2012-09       Impact factor: 2.762

8.  Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.

Authors:  Katsuya Chinen; Takashi Fujino; Ayako Horita; Atsuhiko Sakamoto; Yasunori Fujioka
Journal:  Pathol Res Pract       Date:  2008-10-02       Impact factor: 3.250

9.  Fatal acute pulmonary hypertension caused by pulmonary tumour thrombotic microangiopathy.

Authors:  N G Keenan; A G Nicholson; P J Oldershaw
Journal:  Int J Cardiol       Date:  2007-03-08       Impact factor: 4.164

Review 10.  Pulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literature.

Authors:  Eukene Gainza; Sara Fernández; Daniel Martínez; Pedro Castro; Xavier Bosch; José Ramírez; Arturo Pereira; María T Cibeira; Jordi Esteve; Josep M Nicolás
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.